Abstract
The novel folate analogue AG2034, which was designed as an inhibitor of GARFT (glycinamide ribonucleotide formyltransferase), was evaluated in this phase I study under the auspices of The Cancer Research Campaign, UK. AG2034 blocks de novo purine synthesis through inhibition of GARFT. A total of 28 patients with histologically proven intractable cancers were enrolled. AG2034 was administered as a short intravenous infusion once every 3 weeks. 8 dose levels ranging from 1–11 mg/m2 were evaluated with patients receiving up to 6 cycles. Dose-limiting toxicities in the form of mucositis, diarrhoea and vomiting were observed at doses of 6 mg/m2 and above. Significant levels of thrombocytopenia, neutropenia and anaemia were also recorded. Other sporadic toxicities included fatigue and myalgia. The MTD with this schedule of AG2034 was 5 mg/m2. Most side effects occurred more frequently with cumulative dosing. In keeping with this, pharmacokinetic analysis revealed evidence of drug accumulation. The AG2034 AUC0–24 increased by a median of 184% (range 20–389%) from cycle 1 to 3 in all 10 patients examined. No objective antitumour responses were observed in the study. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: folate analogue, AG2034, GARFT inhibitor
Full Text
The Full Text of this article is available as a PDF (63.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- D'Argenio D. Z., Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979 Mar;9(2):115–134. doi: 10.1016/0010-468x(79)90025-4. [DOI] [PubMed] [Google Scholar]
- Laohavinij S., Wedge S. R., Lind M. J., Bailey N., Humphreys A., Proctor M., Chapman F., Simmons D., Oakley A., Robson L. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Invest New Drugs. 1996;14(3):325–335. doi: 10.1007/BF00194536. [DOI] [PubMed] [Google Scholar]
- McLeod H. L., Cassidy J., Powrie R. H., Priest D. G., Zorbas M. A., Synold T. W., Shibata S., Spicer D., Bissett D., Pithavala Y. K. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res. 2000 Jul;6(7):2677–2684. [PubMed] [Google Scholar]
- Ray M. S., Muggia F. M., Leichman C. G., Grunberg S. M., Nelson R. L., Dyke R. W., Moran R. G. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst. 1993 Jul 21;85(14):1154–1159. doi: 10.1093/jnci/85.14.1154. [DOI] [PubMed] [Google Scholar]
- Roberts J. D., Shibata S., Spicer D. V., McLeod H. L., Tombes M. B., Kyle B., Carroll M., Sheedy B., Collier M. A., Pithavala Y. K. Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423–427. doi: 10.1007/s002800051012. [DOI] [PubMed] [Google Scholar]
- Sessa C., de Jong J., D'Incalci M., Hatty S., Pagani O., Cavalli F. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue. Clin Cancer Res. 1996 Jul;2(7):1123–1127. [PubMed] [Google Scholar]
- Synold T. W., Newman E. M., Carroll M., Muggia F. M., Groshen S., Johnson K., Doroshow J. H. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. Clin Cancer Res. 1998 Oct;4(10):2349–2355. [PubMed] [Google Scholar]
- Wedge S. R., Laohavinij S., Taylor G. A., Boddy A., Calvert A. H., Newell D. R. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement. Clin Cancer Res. 1995 Dec;1(12):1479–1486. [PubMed] [Google Scholar]